A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

计划入组 9 人 · 首次发布于 2014 年 10 月 15 日

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

计划入组 13 人 · 首次发布于 2015 年 6 月 3 日

Pegcetacoplan (APL-2) in Neovascular AMD

计划入组 17 人 · 首次发布于 2018 年 3 月 14 日

Pegcetacoplan(Empaveli, Syfovre, Aspaveli)

Rx

Systemic Sclerosis(ImmuneID)

Systemic Mastocytosis(Alys)

Cadrenal Therapeutics

United States

Edesa Biotech

Canada

Entero Therapeutics

Apellis Secures $300 Million in Non-Dilutive Financing Through Sobi Royalty Agreement for Rare Kidney Disease Therapy

Pegcetacoplan Shows Promise in Phase 3 VALIANT Study for Rare Kidney Diseases

Pegcetacoplan Shows Promise in Phase 3 VALIANT Study for Rare Kidney Diseases